RxDoctor Payments Data

Lidia Navarro

Family · Surprise, AZNPI 1417428657

Payments from drug & device makers

$6,657in general payments, 2019–2025

Across 337 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$734
  • Dermavant Sciences, Inc.$494
  • Amgen$461
  • Sanofi$399
  • LEO Pharma Inc.$318
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$6,46197%
  • Education$1953%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,657 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$40,870
Medicare patients
178
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast23$127,286
Dupixent PenDupilumab18$71,271
Dupixent SyringeDupilumab13$47,768
Clobetasol Propionate185$7,912
Ketoconazole200$2,196
Doxycycline Hyclate96$1,960
Metronidazole17$1,591
Clindamycin Phosphate52$1,523
Triamcinolone Acetonide102$942
Tretinoin13$635
Permethrin11$478
Hydrocortisone45$227
Dutasteride14$182
Nystatin14$166
Finasteride30$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$461$127,28623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →